65. Primary immunodeficiency Clinical trials / Disease details


Clinical trials : 482 Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-004518-28-GB
(EUCTR)
08/12/200909/11/2009Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPODInvestigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD Children with chronic granulomatous disease (CGD).
MedDRA version: 9.1;Level: LLT;Classification code 10008906;Term: Chronic granulomatous disease
Trade Name: Noxafil 40 mg/ml oral solution
Product Name: noxafil
INN or Proposed INN: POSACONAZOLE
Radboud University Nijmegen Medical CentreNULLNot RecruitingFemale: yes
Male: yes
20United Kingdom;Netherlands
2NCT00799071
(ClinicalTrials.gov)
February 200926/11/2008Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)Investigation of POsaconazole Prophylaxis in Children With Chronic Granulomatous Disease (CGD): Pharmacokinetics and Tolerability (iPOD)Chronic Granulomatous DiseaseDrug: posaconazole (PSZ)Radboud UniversityNULLCompleted2 Years16 YearsAll12Phase 2Netherlands;United Kingdom
3EUCTR2008-004518-28-NL
(EUCTR)
19/11/200824/11/2008Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPODInvestigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD Children with chronic granulomatous disease (CGD).
MedDRA version: 9.1;Level: LLT;Classification code 10008906;Term: Chronic granulomatous disease
Trade Name: Noxafil 40 mg/ml oral solutionRadboud University Nijmegen Medical CentreNULLNot RecruitingFemale: yes
Male: yes
United Kingdom;Netherlands